tetano
Editor, Senior Moderator
Cureus
. 2022 Mar 31;14(3):e23698.
doi: 10.7759/cureus.23698. eCollection 2022 Mar.
COVID-19 Infection May Not Produce Lasting Immunity in Non-vaccinated Young Adults: A Retrospective Review of COVID-19 Antibody Data
Marisa B DiGiulio[SUP] 1 [/SUP], Rajia Arbab[SUP] 1 [/SUP], Kevin P Driscoll[SUP] 1 [/SUP], John Balmer DO[SUP] 1 2 [/SUP]
Affiliations
Abstract
Background Despite progress in achieving herd immunity through recovery from previous infection and vaccination efforts, the COVID-19 pandemic continues to be an imminent health concern. Exposure to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral antigen through infection or vaccination facilitates immune system efficacy against future infection, but it is currently unclear how long this immunity lasts. Therefore, understanding the necessary exposures to produce adequate antibody levels and the duration of this humoral response to prevent infection is imperative in updating guidelines for vaccination and ultimately ending this public health crisis. Aims This study aimed to compare the presence of serum antibodies in younger and older age groups to determine how vaccination and previous infection compare as indicators of immunity against COVID-19. We also evaluated age to determine its role in antibody presence. We hope that this information will be helpful to the public to develop the best recommendations for vaccination guidelines concerning distinct demographics. Materials and methods In this retrospective data analysis, we evaluated saliva SARS-CoV-2 test results taken from 309 subjects (192F/117M; median age=53.4) during a community fair in Crawford County, PA. We sorted the subjects into groups based on age, reported infection with the COVID-19 virus, and vaccination status. We then performed a Chi-square analysis to compare the frequency of positive SARS-CoV-2 antibody tests within these groups. Results The vaccinated but not previously-infected cohort (n=146, 81.5%) was significantly more likely to have antibodies than the unvaccinated infected cohort (n=55, 65.5%; p<0.0001). In the previously-infected, unvaccinated cohort, individuals who were 55 and older were more likely to have antibodies than younger individuals (p<0.0157), but no age-dependent difference was observed among vaccinated individuals. Conclusions The results suggest that vaccination provides a more durable immune response than recovery from infection, and there is an age-dependent humoral response following previous infection but not vaccination. Practically speaking, this information implies that despite popular misconception, individuals under the age of 55 must receive a COVID-19 vaccine despite the previous infection as they are significantly less likely to have antibodies following infection than their counterparts who are over the age of 55.
Keywords: covid; covid severity; covid-19; covid-19 pandemic; covid-19 prevention; covid-19 spread; covid-19 vaccine; immunology covid 19; recurrence covid 19; sars-cov-2-igg antibodies.
. 2022 Mar 31;14(3):e23698.
doi: 10.7759/cureus.23698. eCollection 2022 Mar.
COVID-19 Infection May Not Produce Lasting Immunity in Non-vaccinated Young Adults: A Retrospective Review of COVID-19 Antibody Data
Marisa B DiGiulio[SUP] 1 [/SUP], Rajia Arbab[SUP] 1 [/SUP], Kevin P Driscoll[SUP] 1 [/SUP], John Balmer DO[SUP] 1 2 [/SUP]
Affiliations
- PMID: 35509999
- PMCID: PMC9060730
- DOI: 10.7759/cureus.23698
Abstract
Background Despite progress in achieving herd immunity through recovery from previous infection and vaccination efforts, the COVID-19 pandemic continues to be an imminent health concern. Exposure to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral antigen through infection or vaccination facilitates immune system efficacy against future infection, but it is currently unclear how long this immunity lasts. Therefore, understanding the necessary exposures to produce adequate antibody levels and the duration of this humoral response to prevent infection is imperative in updating guidelines for vaccination and ultimately ending this public health crisis. Aims This study aimed to compare the presence of serum antibodies in younger and older age groups to determine how vaccination and previous infection compare as indicators of immunity against COVID-19. We also evaluated age to determine its role in antibody presence. We hope that this information will be helpful to the public to develop the best recommendations for vaccination guidelines concerning distinct demographics. Materials and methods In this retrospective data analysis, we evaluated saliva SARS-CoV-2 test results taken from 309 subjects (192F/117M; median age=53.4) during a community fair in Crawford County, PA. We sorted the subjects into groups based on age, reported infection with the COVID-19 virus, and vaccination status. We then performed a Chi-square analysis to compare the frequency of positive SARS-CoV-2 antibody tests within these groups. Results The vaccinated but not previously-infected cohort (n=146, 81.5%) was significantly more likely to have antibodies than the unvaccinated infected cohort (n=55, 65.5%; p<0.0001). In the previously-infected, unvaccinated cohort, individuals who were 55 and older were more likely to have antibodies than younger individuals (p<0.0157), but no age-dependent difference was observed among vaccinated individuals. Conclusions The results suggest that vaccination provides a more durable immune response than recovery from infection, and there is an age-dependent humoral response following previous infection but not vaccination. Practically speaking, this information implies that despite popular misconception, individuals under the age of 55 must receive a COVID-19 vaccine despite the previous infection as they are significantly less likely to have antibodies following infection than their counterparts who are over the age of 55.
Keywords: covid; covid severity; covid-19; covid-19 pandemic; covid-19 prevention; covid-19 spread; covid-19 vaccine; immunology covid 19; recurrence covid 19; sars-cov-2-igg antibodies.